RTI Biologics, Inc. (RTIX) Reports In-Line Q4 EPS; Guides Q1, FY13
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q4 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $44.6 million versus the consensus estimate of $45.14 million.
Sees FY2013 EPS of $0.17-$0.19, versus the consensus of $0.22. RTI Biologics sees FY2013 revenue of $178-$182 million, versus the consensus of $188.39 million.
Sees Q1 2013 EPS of $0.02, versus the consensus of $0.05. RTI Biologics sees Q1 2013 revenue of $38-$39 million, versus the consensus of $45.90 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
Sees FY2013 EPS of $0.17-$0.19, versus the consensus of $0.22. RTI Biologics sees FY2013 revenue of $178-$182 million, versus the consensus of $188.39 million.
Sees Q1 2013 EPS of $0.02, versus the consensus of $0.05. RTI Biologics sees Q1 2013 revenue of $38-$39 million, versus the consensus of $45.90 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
- Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
